Zunyi Medical University

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy (2021) Zhou JG, Liang B, Liu JG, Jin SH, He SS, Frey B, Gu N, et al. Journal article The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Journal article, Review article Screening and validation of a novel T stage-lymph node ratio classification for operable colon cancer. (2021) Pei JP, Zhang R, Zhang NN, Zeng YJ, Sun Z, Ma SP, Zhou JG, et al. Journal article Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma. (2021) Yu Y, Zeng Y, Xia X, Zhou JG, Cao F Journal article Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Conference contribution Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors (2020) Zhou JG, Ma H, Gaipl U Conference contribution Development of an immunological prognostic Signature in metastatic Patients who were treated with Immune Checkpoint Inhibitors as part of the ST-ICI Study (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Development and Validation of a Gene Signature for Prediction of Relapse in Stage I Testicular Germ Cell Tumors (2020) Zhou JG, Yang J, Jin SH, Xiao S, Shi L, Zhang TY, Ma H, Gaipl U Journal article Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials (2020) Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, Gaipl U Journal article, Review article